About 1.5 million people died of tuberculosis (TB) in 2017, making it the most lethal infectious disease worldwide. A growing rise in drug-resistant TB is a major obstacle to successfully treating the illness.
Now, researchers at Washington University School of Medicine in St. Louis and Umea University in Sweden have found a compound that prevents and even reverses resistance to isoniazid, the most widely used antibiotic for treating tuberculosis.
The research, published the week of May 6 in Proceedings of the National Academy of Sciences, was conducted in bacteria growing in the lab, setting the stage for future studies in animals and people.
Using the compound in conjunction with isoniazid potentially could restore the antibiotic’s effectiveness in people with drug-resistant tuberculosis. The compound also may bolster the antibiotic’s power to kill TB bacteria – even those sensitive to drugs – which means doctors could start thinking about cutting down the onerous six-month treatment regimen they prescribe today.
“It is very hard for people to comply with such a long regimen,” said co-senior author Christina Stallings, PhD, an associate professor of molecular microbiology at the School of Medicine. “It’s four drugs. They have side effects. It’s no fun. The longer people have to be on antibiotics, the more issues with patient compliance you get, and that can lead to drug resistance and treatment failure. Here, we’ve found a compound that sensitizes bacteria to an antibiotic, prevents drug resistance from arising, and even reverses drug resistance – at least in the lab. If we can turn this compound into a drug for people, it could make our current therapies more effective and be really beneficial for fighting this pandemic.”
Tuberculosis is caused by the bacterium Mycobacterium tuberculosis. Once inside the body, the bacteria morph into a tougher form that can withstand more stress and is harder to kill. Rather than look for new and better antibiotics, Stallings and co-first authors Kelly Flentie, PhD, a former postdoctoral researcher at Washington University, and Gregory Harrison, a graduate student, decided to look for compounds that prevent the bacteria from toughening up. When put in a low-oxygen environment to mimic the stressful conditions TB bacteria encounter inside the body, the bacteria come together and form a thin film called a biofilm that is resilient to not only low-oxygen conditions but also to antibiotics and other stressors.
With the help of co-senior author Fredrik Almqvist, PhD, a professor of chemistry at Umea University, they screened 91 compounds that share a core chemical structure that inhibits biofilms in other bacterial species. The researchers found one compound, called C10, that did not kill the TB bacteria but prevented them from forming a biofilm.
Further experiments showed that blocking biofilm formation with C10 made the bacteria easier to kill with antibiotics and even curbed the development of antibiotic resistance. The researchers needed only a fraction of the amount of isoniazid to kill the TB bacteria when C10 was included than with isoniazid alone. In addition, one out of 1 million TB bacteria spontaneously become resistant to isoniazid when grown under typical laboratory conditions. But when the researchers grew TB bacteria with isoniazid and the compound, the drug-resistant mutant bacteria never arose.
“By combining C10, or something like it, with isoniazid we could enhance the potency of the antibiotic and block the TB bacteria from developing drug resistance,” Stallings said. “That means we might be able to shorten the treatment regimen.”
Most surprisingly, the compound even reversed drug resistance. TB bacteria with mutations in the gene katG can withstand isoniazid treatment. But such bacteria die when treated with isoniazid plus the compound, the researchers discovered. The bacteria had not lost their genetic resistance, but they’d lost the ability to survive when exposed to isoniazid, as long as it was given alongside C10.
“This was a totally unexpected finding,” Stallings said. “We had no idea we would be able to reverse drug resistance. But this could mean that with all those millions of isoniazid-resistant TB cases, if we use something like C10, we could give people the option of using isoniazid again.”
The compound is not ready to be used in people or even tested in animals, Stallings cautioned. This study was conducted on bacteria growing in a lab. The researchers are still figuring out whether the compound is safe and how it might be processed by the body.
“We have this great compound, and we’ve shown that it’s possible to prevent and reverse antibiotic resistance,” Stallings said. “But now we have to either improve on the compound itself so we can start testing it in animals, or figure out how it prevents biofilm formation so we can develop other drugs that target the pathway. We have a new strategy to treat TB, but it’s going to take time before it’s a reality.”
The Latest on: Drug-resistant TB
via Google News
The Latest on: Drug-resistant TB
- 27,000 new TB cases report every year on May 20, 2019 at 3:24 am
He said more than three hundred thousand TB patients are benefiting free diagnostic and treatment facilities every year in Pakistan. He said more than 30 hospitals have been upgraded to take care of ... […]
- A good price to pay: An $8 billion investment could cure tuberculosis by 2045 on May 18, 2019 at 4:30 am
There was a brief period of hope that TB could be eradicated in the early 20th century, but the rise of drug-resistant strains in the 1980s reinvigorated the disease’s devastating reach. So ... […]
- Could better tests help reverse the rise of drug-resistant infections? on May 16, 2019 at 11:04 am
A growing number of infections—such as pneumonia, gonorrhea and tuberculosis—are becoming ... more accurate tests for drug-resistant infections are being developed that could, at least in ... […]
- New tech for tuberculosis patients on May 16, 2019 at 1:50 am
Some patients carry a drug-resistant strain of the TB bacteria which does not respond to one or more of the four usual antibiotics. Those patients work with their doctors to find effective treatments, ... […]
- Researchers identify faster, more effective drug combinations for tuberculosis on May 14, 2019 at 4:17 am
Even worse, there is a high fatality rate among those with drug-resistant TB. In new research, UCLA scientists have reported finding a way to significantly reduce the duration of treatment by ... […]
- Ondo records 800 cases of drug-resistant tuberculosis on May 13, 2019 at 4:06 pm
The Ondo State Government has said that it recorded 800 cases of drug-resistant tuberculosis infection in the state. Governor Rotimi Akeredolu, who stated this during the biennial general meeting ... […]
- Researchers identify faster, more effective drug combination regimens to treat tuberculosis on May 13, 2019 at 6:44 am
Even worse, there is a high fatality rate among those with drug-resistant TB. In new research, UCLA scientists have reported finding a way to significantly reduce the duration of treatment by using an ... […]
- Engineered phages stymie drug-resistant infection on May 9, 2019 at 12:27 pm
Drug-resistant TB strains are an especially tempting target for phage therapy. M. abscessus and other bacteria often colonize the thick mucus that builds up in the lungs of people with cystic fibrosis ... […]
- Warning over global failure to act on growing number of deaths from drug-resistant TB on May 9, 2019 at 4:48 am
The spiralling number of deaths from drug-resistant tuberculosis (DR-TB) is set to cost the world economy nearly $20billion annually. A report from the Economist Intelligence Unit warned that despite ... […]
- TB Alliance and partners form multidisciplinary center for translational TB drug research on May 9, 2019 at 2:07 am
In 2017, 10 million people fell ill from active TB and 1.6 million people died. Drug-resistant TB is on the rise, with more than half a million cases of MDR-TB reported in 2017. The epidemic is ... […]
via Bing News